INDIVIOR PLC/S (OTCMKTS:INVVY) – Equities researchers at Jefferies Financial Group issued their FY2023 earnings per share (EPS) estimates for shares of INDIVIOR PLC/S in a report issued on Monday, February 18th. Jefferies Financial Group analyst J. Vane-Tempest expects that the company will earn $0.95 per share for the year. Jefferies Financial Group currently has a “Hold” rating on the stock.
INDIVIOR PLC/S (OTCMKTS:INVVY) last posted its earnings results on Thursday, February 14th. The company reported $0.45 earnings per share for the quarter. The company had revenue of $236.00 million during the quarter.
INDIVIOR PLC/S stock opened at $6.90 on Wednesday. INDIVIOR PLC/S has a fifty-two week low of $4.73 and a fifty-two week high of $33.83. The company has a market capitalization of $1.06 billion, a P/E ratio of 3.83 and a beta of 0.34.
About INDIVIOR PLC/S
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, overdose rescue, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.
Featured Article: What is the Current Ratio?
Receive News & Ratings for INDIVIOR PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INDIVIOR PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.